57.40SEK+3.05%Mkt Cap: 767.87M SEKP/E: —Last update: 2026-05-13
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug c…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
P/B7.29
P/S—
EV/EBITDA—
EV/Revenue—
EPS (TTM)-5.30
EPS (Forward)—
Cash Flow & Leverage
FCF Yield-4.63%
FCF Margin—
Operating CF-72.34M SEK
CapEx (TTM)—
Net Debt/EBITDA—
Net Debt-131.93M SEK
Technical
SMA 5051.72 (+11.0%)
SMA 20054.96 (+4.4%)
Beta—
S&P 52W Chg24.23%
Avg Vol (30d)11.00K
Avg Vol (10d)21.07K
Technical Indicators
RSI (14)59.4
MACD1.3533
MACD Signal1.2883
MACD Hist.+0.0650
BB Upper58.35 SEK
BB Middle54.71 SEK
BB Lower51.07 SEK
BB Width13.32%
ATR (14)3.704 SEK
Vol Ratio (20d)0.50x
52W Range
43.2534% of range84.30
52W High84.30 SEK
52W Low43.25 SEK
Profitability
Gross Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
Oper. Margin0.00%
ROE-61.87%
ROA-40.29%
Revenue Growth—
Earnings Growth—
Balance Sheet
Debt/Equity—
Current Ratio2.23
Quick Ratio2.21
Book Value/Sh7.819 SEK
Cash/Share9.793 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.13.02M
Float11.23M
Insiders17.49%
Institutions32.32%
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Company
Market Cap767.87M SEK
Enterprise Value635.94M SEK
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-65.17M SEK
Revenue/Share—
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees6
Last Price57.40 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—